With new data, Exelixis takes another shot at prostate cancer treatment

0 15

In 2014, the Bay Area biotech company Exelixis (EXEL) tried to develop a drug for prostate cancer; its clinical trial ended in failure and nearly shut down the company. A second attempt has delivered better, tumor-shrinking results, according to data released Monday, while still leaving some important questions unanswered.

In an interim look at the ongoing study, a combination regimen consisting of Exelixis’ targeted cancer drug Cabometyx and Roche’s checkpoint inhibitor Tecentriq demonstrated a tumor response rate of 32%. The median duration of response was 8.3 months.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


Cet article est apparu en premier sur https://www.statnews.com/2020/02/10/new-combination-drug-data-exelixis-prostate-cancer/

Laisser un commentaire

Votre adresse email ne sera pas publiée.